NasdaqGS - Delayed Quote USD

Vaxcyte, Inc. (PCVX)

60.88 -0.72 (-1.17%)
At close: April 23 at 4:00 PM EDT
60.88 0.00 (0.00%)
After hours: April 23 at 4:45 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
388,276.00
388,276.00
207,330.00
102,085.00
87,103.00
Operating Income
-388,276.00
-388,276.00
-207,330.00
-102,085.00
-87,103.00
Net Non Operating Interest Income Expense
62,907.00
62,907.00
8,354.00
337.00
237.00
Other Income Expense
-76,897.00
-76,897.00
-24,509.00
1,671.00
-2,351.00
Pretax Income
-402,266.00
-402,266.00
-223,485.00
-100,077.00
-89,217.00
Net Income Common Stockholders
-402,266.00
-402,266.00
-223,485.00
-100,077.00
-89,217.00
Diluted NI Available to Com Stockholders
-402,266.00
-402,266.00
-223,485.00
-100,077.00
-89,217.00
Basic EPS
-4.14
-4.14
-3.44
-1.93
-3.02
Diluted EPS
-4.14
-4.14
-3.44
-1.93
-3.02
Basic Average Shares
97,157.69
97,157.69
64,877.99
51,922.11
29,545.81
Diluted Average Shares
97,157.69
97,157.69
64,877.99
51,922.11
29,545.81
Total Operating Income as Reported
-468,041.00
-468,041.00
-232,256.00
-103,670.00
-89,581.00
Total Expenses
388,276.00
388,276.00
207,330.00
102,085.00
87,103.00
Net Income from Continuing & Discontinued Operation
-402,266.00
-402,266.00
-223,485.00
-100,077.00
-89,217.00
Normalized Income
-325,369.00
-325,369.00
-198,976.00
-101,748.00
-86,866.00
Interest Income
62,907.00
62,907.00
8,356.00
344.00
244.00
Interest Expense
--
--
2.00
7.00
7.00
Net Interest Income
62,907.00
62,907.00
8,354.00
337.00
237.00
EBIT
-402,266.00
-402,266.00
-223,483.00
-100,070.00
-89,210.00
EBITDA
-392,095.00
-392,095.00
-214,287.00
-96,613.00
-87,805.00
Reconciled Depreciation
10,171.00
10,171.00
9,196.00
3,457.00
1,405.00
Net Income from Continuing Operation Net Minority Interest
-402,266.00
-402,266.00
-223,485.00
-100,077.00
-89,217.00
Total Unusual Items Excluding Goodwill
-76,897.00
-76,897.00
-24,509.00
1,671.00
-2,351.00
Total Unusual Items
-76,897.00
-76,897.00
-24,509.00
1,671.00
-2,351.00
Normalized EBITDA
-315,198.00
-315,198.00
-189,778.00
-98,284.00
-85,454.00
12/31/2020 - 6/12/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NUVL Nuvalent, Inc.
67.60
+4.82%
 
ASND Ascendis Pharma A/S
144.83
+1.92%
 
IMCR Immunocore Holdings plc
57.31
+2.67%
 
BPMC Blueprint Medicines Corporation
92.29
+1.85%
 
REPL Replimune Group, Inc.
6.42
0.00%
 
LEGN Legend Biotech Corporation
47.45
+0.83%
 
ORIC ORIC Pharmaceuticals, Inc.
8.77
+0.57%
 
KROS Keros Therapeutics, Inc.
55.19
-1.06%
 
RVMD Revolution Medicines, Inc.
36.26
-0.47%
 
RYTM Rhythm Pharmaceuticals, Inc.
40.00
+2.54%